WV HB2410

Expands eligibility for experimental treatments from patients with "terminal illness" to those with "life-threatening or severely debilitating illness" as defined in federal regulations (21 C.F.R. § 312.81)

Removes the requirement that patients must first attempt to participate in a clinical trial within 100 miles of their home or be rejected from a trial within one week

Broadens the definition of "investigational drug, biological product or device" to include individualized treatments based on a patient's genetic profile, such as gene therapy antisense oligonucleotides and neoantigen vaccines

Repeals the legislative findings section (§16-51-2) of the existing Right-to-Try Act

Maintains requirements for written informed consent, physician recommendation, and consideration of all FDA-approved treatment options before accessing experimental treatments